A phase II study of bevacizumab, irinotecan and capecitabine in patients with previously untreated metastatic colorectal cancer

Trial Profile

A phase II study of bevacizumab, irinotecan and capecitabine in patients with previously untreated metastatic colorectal cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Oct 2011

At a glance

  • Drugs Bevacizumab; Capecitabine; Irinotecan
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms XELIRI-A
  • Most Recent Events

    • 06 Oct 2011 Actual end date (Jul 2011) added as reported by ClinicalTrials.gov.
    • 06 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 18 Feb 2009 Planned end date changed from 1 Jul 2008 to 1 Jul 2009 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top